WO2004112757A1 - Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug - Google Patents

Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug Download PDF

Info

Publication number
WO2004112757A1
WO2004112757A1 PCT/CA2004/000561 CA2004000561W WO2004112757A1 WO 2004112757 A1 WO2004112757 A1 WO 2004112757A1 CA 2004000561 W CA2004000561 W CA 2004000561W WO 2004112757 A1 WO2004112757 A1 WO 2004112757A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
alkyl
poly
butyl
supramolecular assemblies
Prior art date
Application number
PCT/CA2004/000561
Other languages
French (fr)
Inventor
Vinayak Sant
Jean-Christophe Leroux
Original Assignee
Universite De Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite De Montreal filed Critical Universite De Montreal
Priority to EP04727195A priority Critical patent/EP1638539B1/en
Priority to SI200431088T priority patent/SI1638539T1/en
Priority to CA2530736A priority patent/CA2530736C/en
Priority to DK04727195T priority patent/DK1638539T3/en
Priority to PL04727195T priority patent/PL1638539T3/en
Priority to MXPA05014017A priority patent/MXPA05014017A/en
Priority to JP2006515571A priority patent/JP4619357B2/en
Priority to AU2004248863A priority patent/AU2004248863B2/en
Priority to BRPI0411872-3A priority patent/BRPI0411872A/en
Priority to DE602004018772T priority patent/DE602004018772D1/en
Publication of WO2004112757A1 publication Critical patent/WO2004112757A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to stimuli responsive amphiphilic polymers forming supramolecular assemblies or micelles in the nanometric size range under favourable conditions. These supramolecular assemblies or micelles can be useful for the oral or parenteral delivery of hydrophobic or cationic pharmaceutical agents.
  • Amphiphilic block copolymers having optimal hydrophilic and hydrophobic segments self-assemble spontaneously in aqueous environment forming micelles or supramolecular assemblies. These supramolecular assemblies exhibit core-shell architecture wherein the hydrophobic part forms the core and the hydrophilic part forms the corona.
  • polymeric micelles have been widely used as drug delivery carriers for parenteral administration. Micellar dmg delivery carriers have several advantages including biocompatibility, solubilization of hydrophobic drugs in the core, nanometric size ranges which facilitate extravasation of the dmg carrier at the site of inflammation, site-specific delivery etc.
  • block copolymers for parenteral delivery examples include poly(ethylene oxide)-b-poly(D,L-lactide), poly(ethylene oxide)-b-poly( ⁇ -caprolactone), poly(ethylene oxide)-b-poly(aspartic acid), poly(N-vinyl pyrrolidone)-b-poly(D,L-lactide) etc.
  • US Patent 6,322,805 describes polymeric dmg carrier micelles prepared from amphiphilic block copolymer having a hydrophilic poly(alkylene oxide) component and a biodegradable hydrophobic component selected from a group consisting of poly(lactic acid), poly(lactic-co-glycolic acid), poly( ⁇ -caprolactone) and a derivative thereof. These micelles are capable of solubilizing hydrophobic dmg in a hydrophilic environment.
  • US Patent 6,338,859 describes polymeric micelle compositions where the hydrophilic component includes poly(N-vinyl-2-pyrrolidone) and the hydrophobic component is selected from a group consisting of polyesters, polyorthoesters, polyanhydride and derivatives thereof.
  • the polyester group can be selected from poly(D,L- lactic acid), poly(glycolic acid), lactide/glycolide copolymers, poly( ⁇ -caprolactone) and derivatives thereof.
  • the micelle composition contains a therapeutic agent which can be an antitumor compound, hydrophobic antibiotic, hydrophobic antifungal agent, an immunomodulator, an antiviral dmg , or the like.
  • US Patent 6,383,811 describes formation of complexes of polyions such as DNA with polyampholytes i.e. polymers possessing both cationic and anionic moieties, and delivery of the complex into the cell.
  • US Patent 6,210,717 describes a composition composed of mixed polymeric micelles made of amphiphilic polyester-polycation copoly er and an amphiphilic polyester-sugar copolymer for delivery of nucleic acids into targeted host cells.
  • the polyester-polycation forms an electrostatic interaction with polyanionic nucleic acids, and the polyester-sugar copolymer directs the micelle-nucleic acid complex to cells in vivo.
  • US Patent 6,429,200 describes delivery of polynucleotides to cells using cleavable reverse micelles. Other molecules such as polymers, and surfactants containing disulphide linkages can be included into the complex micelles to enhance the delivery.
  • US Patent 5,510,103 describes block copolymers having the hydrophilic and hydrophobic segments forming micelles and entrapping the hydrophobic drugs by physical methods.
  • the hydrophilic segment is preferably poly(ethylene oxide) and hydrophobic segment is preferably poly( ⁇ -benzyl -L-aspartate) while the preferred dmg is adriamycin.
  • US Patent 5,955,509 describes use of poly(vinyl-N-heterocycle)-b-poly(alkylene oxide) copolymers in micelle containing pharmaceutical formulations. These copolymers respond to pH changes in the environment and can be used to deliver therapeutic compounds at lower pH values. The micelles of these polymers remain intact at neutral pH, e.g.
  • US Patent 6,497,895 describes hyperbranched micelles containing a core of mucic acid esters for the encapsulation of hydrophobic molecules. These polymers are useful for the transdermal delivery of the entrapped agent in a controlled manner.
  • US Patent 6,387,406 describes compositions of the poly(oxyethylene)- poly(oxypropylene) block copolymers for oral delivery of biological agents.
  • Nishiyama et al (Phar Res 2001, 18, 1035-1041 ; J Controlled Release 2001, 74, 83-94) have described the use of poly(ethylene oxide)-b-poly( ⁇ , ⁇ -aspartic acid) block copolymers forming micelles by interaction with an antitumor dmg, specifically cisplatin. Though the majority of these polymers can be used for oral delivery of bioactive agents, what is presently lacking are amphiphilic polymers capable of forming supramolecular assemblies that respond to an environmental stimuli such as pH change, thereby entrapping the contents in the micelle core at a low pH, such as that prevailing in the stomach, and rapidly releasing the contents at a higher pH, such as that prevailing in the intestine.
  • an environmental stimuli such as pH change
  • the present invention relates to polymers useful in combination with pharmaceutical compositions containing at least one biologically active agent. More particularly, the invention relates to block copolymers having hydrophilic and hydrophobic segments suitable for, but not limited to, oral drag delivery. More particularly, the hydrophilic segment of the polymers is nonionic and the hydrophobic segment contains at least one reversibly ionizable pendant carboxyl group conferring pH-sensitivity to the polymers. Accordingly, it is a primary objective of the instant invention to provide a copolymerf which is composed of a hydrophilic segment made of poly(ethylene oxide) and a hydrophobic segment composed of vinyl monomers containing at least one pendant carboxyl group.
  • the vinyl monomers included in the polymer are acrylic acid or methacrylic acid having pendant carboxyl groups and butyl (alkyl)acrylate where the butyl segment can be a linear or branched chain.
  • the hydrophobic segment is a mixture of non-ionizable butyl (alkyl)acrylate and ionizable (alkyl)acrylic acid which controls the hydrophobicity of the polymer.
  • Another objective of the instant invention is to prepare pharmaceutical compositions from the instantly disclosed polymers by entrapping at least one substance, preferably a biologically active agent, which is illustrated by, albeit not limited to a hydrophobic molecule, a cationic compound or macromolecule such as peptides and proteins bearing cationic residues.
  • the entrapment can be physical (e.g. hydrophobic interaction, electrostatic interaction), or chemical (e.g. covalent linkage) in nature.
  • a further objective of the present invention is to prepare supramolecular assemblies having core-shell structure wherein th ⁇ icore is formed by the hydrophobic segment, which can reversibly dissociate and associate in response to a change in environmental pH because of the pendant carboxyl group.
  • the size of these supramolecular assemblies can be between 5 to 1000 nanometers thereby forming a solution or colloidal dispersion in water. It is to be noted that in the further text terms "micelles” and “supramolecular assemblies” are used interchangeably and essentially mean structures having a size range of between about 5 to 1000 nanometers.
  • Yet another objective of the instant invention is to describe methods of entrapping the hydrophobic agents and cationic molecules in the supramolecular assemblies giving high incorporation efficiencies.
  • a still further objective of the present invention is to use these supramolecular assemblies for delivery of a bioactive agent into the body by, but not limited to, the oral route.
  • the hydrophobic molecule trapped in the core of the supramolecular assembly will be protected from the harsh acidic conditions of the stomach and released in the intestine due to dissociation of micelle at high pH.
  • Figure 1 demonstrates in vitro release of progesterone from PEO-b-poly(nBAso-co- MAA 50 ) supramolecular assemblies as a function of pH;
  • Figure 2 demonstrates the effect of pH on intensity of light scattered by solution of PEO- b-poly(nBA5o-co-MAA 5 o);
  • Figure 3. is a plot of plasma concentration versus time of fenofibrate upon oral administration of different formulations to Sprague-Dawley rats.
  • nBA - n-butyl acrylate MAA - methacrylic acid
  • EA - ethyl acrylate PEO - poly(ethylene oxide).
  • the present invention describes pharmaceutical compositions composed of block polymers composed of a poly(ethylene oxide) forming the hydrophilic segment and a poly(butyl (alkyl)acrylate-co-(alkyI)acrylic acid) forming the hydrophobic segment; and at least one biologically active agent.
  • the molecular weight of the hydrophilic segment can be in the range of 200 to 80,000 Da, more preferably in the range of 500 to 10,000 Da, still more preferably in the range of 2,000 to 5,000 Da.
  • the hydrophobic segments of the polymers in the present invention are composed of butyl (alkyl)acrylate and (alkyl)acrylic acid, where the alkyl chain is composed of from 0 to about 10 carbon atoms, inclusively, more preferably with 0 or 1 carbon atom.
  • the butyl segment of the butyl (alkyl)acrylate can be a linear or branched chain including without limitation n-butyl and tert-butyl groups.
  • the mole ratio of the butyl (alkyl)acrylate : (alkyl)acrylic acid in the hydrophobic segment is in the range of about 5:95 to 95:5, more preferably in the range of about 30:70 to 70:30.
  • the length of the hydrophobic segment can be in the range of about 200 to 50,000, more preferably in the range of about 500 to 80,000 Da.
  • Amphiphilic block copolymers have a tendency to self-assemble in water forming micelles. Upon micellization, the hydrophobic segment forms a core and the hydrophilic segment forms the corona of the micelles. The core of these micelles can be used as a reservoir of hydrophobic compounds protecting them form the external environment. If the hydrophobic segment of the polymer contains reversibly ionizable moieties, then the hydrophobicity of the segment could be manipulated by controlling the ionization of the moiety. Polymers of the present invention differ from other block copolymers in this aspect.
  • the hydrophobic segment is composed of the mixture of two monomers, one of them is butyl (alkyl) acrylate, which confers hydrophobicity to the segment.
  • Butyl (alkyl)acrylate monomer is more preferably butyl acrylate or butyl methacrylate.
  • the other monomer, (alkyl)acrylic acid has a pendant carboxyl group that can be reversibly ionized by changing the environmental pH.
  • the environmental pH is below the pKa of the carboxyl group, it will remain mostly in the unionized form and will confer hydrophobicity to the segment. This results in spontaneous aggregation of polymeric chains forming stable supramolecular assemblies or micelles in aqueous environment.
  • (Alkyl)acrylic acid monomer is more preferably acrylic acid or methacrylic acid.
  • These supramolecular assemblies are in the size range of from about 5 to 1000 nanometers. Hydrophobic drags are incorporated in the core of such supramolecular assemblies by methods that are known to one of ordinary skill in the art (see for example Lavasanifar et al J Controlled Release 2001, 77,155-60; Kohori et J Controlled Release 2002,78,155-63).
  • Manipulation of the composition of the hydrophobic segment results in variation in the hydrophobicity of the polymer allowing control of the incorporation efficiencies of the hydrophobic drugs.
  • Loadings in the range of 0.1 to 50% w/w more preferably in the range of 1 to 20% w/w of hydrophobic drugs are obtained using different drug loading procedures.
  • Block copolymers of the present invention are used to prepare pharmaceutical compositions containing hydrophobic molecules.
  • Non-limiting examples of the hydrophobic molecules includes hypolipidemic agents such as fenofibrate, anticancer agents such as doxorubicin, paclitaxel, docetaxel, camptothecin, megestrol acetate, teniposide, etoposide, antihypertensive agents such as candesartan cilexetil, non-steroidal, anti-inflammatory agents such as indomethacin, celecoxib, antiviral agents such as retinovir, amprenavir, indinavir, efavirenz, immunosuppressive agents such as cyclosporin A, sirolimus, tacrolimus, and similar agents belonging to other therapeutic classes.
  • hypolipidemic agents such as fenofibrate
  • anticancer agents such as doxorubicin, paclitaxel, docetaxel, camptothecin, megestrol acetate, teniposide, etoposide, antihypertensive
  • the poly(butyl (alkyl)acrylate-co-(alkyl)acrylic acid) segment of the polymer will bear a negative charge at a pH above the pKa of carboxyl groups and form complexes with cationic molecules including without limitation polycations, peptides and proteins bearing cationic residues by electrostatic interactions. This will result in the partial or complete charge neutralization of polymer and/or cationic molecule thereby forming supramolecular assemblies or micelles. The cation or polycationic molecule will be entrapped in the core of such supramolecular assemblies.
  • cationic residues refers to the functional groups imparting positive charge to the molecule such as cationic amino acids e.g.
  • lysine arginine, histidine or other functional groups such as primary, secondary, tertiary or quaternary amine groups present in the molecule.
  • the complexes of poly(ethylene oxide)-block-poly(n-butyl acrylate-co-methacrylic acid) with poly-1-lysine are prepared in a buffer solution at pH 7.4.
  • Supramolecular assemblies having unimodal size distribution within the size range of about 20 to 50 nm are obtained depending upon the molecular weight of the poly-1-lysine and composition of the polymer.
  • complexes of poly(ethylene oxide)-block-poIy(ethyl acrylate-co-methacrylic acid) with poly-1-lysine in pH 7.4 buffer results in formation of aggregates having multimodal size distribution with sizes above about 200 nm.
  • block copolymers are used to form stable coordination complexes with biologically active agents illustrated as metallic compounds such as cisplatin, carboplatin above the pKa of the carboxyl groups.
  • biologically active agents illustrated as metallic compounds such as cisplatin, carboplatin above the pKa of the carboxyl groups.
  • the presence of butyl (alkyl)acrylate in the hydrophobic segment plays several crucial roles in forming stable supramolecular assemblies.
  • polymers with improved characteristics could be obtained by incorporating butyl (alkyl)acrylate in the hydrophobic segment.
  • One of the major advantages of polymers in accordance with the present invention is the presence of the butyl chain of the butyl (alkyl)acrylate that largely minimizes formation of such hydrogen bonding complexes and can prevent formation of aggregates. This aids in the formation of stable supramolecular assemblies having uniform size range.
  • poly(ethylene oxide)-block-poly(n-butyl acrylate-co-methacrylic acid) with 50:50 mole ratio of n-butyl acrylate:methacrylic acid having molecular weight of about 5300 Da forms micelles of 30 nm at pH 5.0
  • poly(ethylene oxide)-block- poly(ethyl acrylate-co-methacrylic acid) with 50:50 mole ratio of ethyl acrylate: methacrylic acid having molecular weight of about 5100 Da forms micelles of 120 nm at pH 5.0, which are possibly aggregates of several micelles.
  • An oral route is the most preferred route of administration for a pharmaceutically active agent.
  • compositions can be used in the form of tablets, capsules, powders, lozenges, solutions, suspensions, syrups, elixirs, and the like.
  • the pharmaceutical compositions of the present invention are administered orally.
  • the pharmaceutical compositions of the present invention can also be administered by a number of other routes, including without limitation, rectally, vaginally, topically, by pulmonary route, parenterally, including but not limited to intravenous, intra-arterial, intramuscular, intraperitoneal or subcutaneous route.
  • the polymers in the present invention can be modified to attach targeting ligands such as lectin, antibodies or fragments of antibodies, peptides, vitamins or sugar molecules.
  • figures appearing as subscript in the polymer composition indicate the mole ratio of that monomer present in the hydrophobic segment of the polymer.
  • Progesterone was used as a model hydrophobic drug to evaluate the effect of pH on drug release from supramolecular assemblies.
  • 3 H-progesterone was loaded in the supramolecular assemblies of PEO-b-poly(nBA 5 o-co-MAA 5 o) of molecular weight 5300 Da by film casting method. Briefly, 10 mg polymer, 1 mg progesterone and 1 ⁇ Ci 3 H- progesterone were dissolved in a mixture of dichloromethane, ethanol and water in a scintillation vial. The solvents were evaporated under reduced pressure to cast a film of polymer and drug on the glass surface.
  • the film was hydrated with water to obtain the supramolecular assemblies, this solution was filtered through 2 ⁇ m filter to remove precipitated drag.
  • the solution of progesterone loaded supramolecular assemblies was filled in a dialysis bag (6000-8000 Da molecular weight cut off) and the bag was put in a beaker containing 200 mL of simulated gastric fluid, pH 1.2 maintained at 37°C.
  • the release medium was magnetically stirred. After 2 hours, the pH of medium was adjusted to 7.2 by addition of sodium hydroxide and potassium dihydrogen phosphate. During the entire release experiment, 1 mL samples of release medium were withdrawn periodically to measure the radioactivity of 3 H-progesterone.
  • Fenofibrate was used as a model poorly water-soluble hydrophobic drug to evaluate the effect of drug incorporation in supramolecular assemblies on the bioavailability upon oral administration to rats.
  • FNB incorporation was studied in different PEO-b-poly(EA-co-MAA) and PEO-b-poly(nBA5 ⁇ r CO-MAA 50 ) polymers by emulsion and film casting methods. The FNB loading was higher in PEO-b-poly(nBA5o-co-MAA5o) polymers.
  • FNB loaded supramolecular assemblies were prepared from PEO-b-poIy(nBAso-co-MAA 5 o) of about molecular weight 5300 Da by film casting method. Size of the supramolecular assemblies was in the range of about 100-300 nm.
  • FNB standard formulation was prepared by suspending the powder from Lipidil Macro® (Foumier) capsule in 0.5% w/v , carboxymethyl cellulose sodium (CMC Na) solution to obtain uniform suspension.
  • FNB powder (Sigma) was also suspended in 0.5% w/v CMC Na solution to prepare resuspended FNB formulation which acts as a negative control. Rats were divided into 3 groups of 6 animals each. The rats were fasted overnight and fed with standard diet throughout the study. Each formulation was administered orally at a dose of 7.5 g/kg to 6 rats from a group. Blood was removed periodically from each rat, plasma was separated and stored at -80°C till further use. FNB content from the plasma was determined and plotted against time, the results of which are shown in Figure 3.
  • Example 3 Formation of polyion complex micelles of PEO-ft-P(nBAso-co-MAAso) with poly-l- lysine
  • Poly-1-lysine (PLL) of molecular weight 16,100 was used as a model cationic compound for formation of polyion micelles with PEO-b-P(EA 50 -co-MAA5o) and PEO-b-P(nBA5o-co- MAA 50 ) copolymers with molecular weights of 5100 and 5700 Da, respectively.
  • Polymer: PLL (-/+) charge ratios (mole: mole) of 1 : 1 and 2: 1 were used for complex formation.
  • Example 4 Complexation of PEO-b-P(nBA so -co-MAA S o) with verapamil hydrochloride
  • Verapamil hydrochloride was used as a model cationic drug. Solutions of PEO-b-P(nBA 50 - co-MAA 50 ) and verapamil hydrochloride in universal buffer were mixed to obtain final polymer concentration of 0.5 mg/mL and verapamil hydrochloride concentration of 0.8 mg/mL. The solution pH was adjusted to 6.1 and size was measured using DLS. Polyion complex micelles of 38 ⁇ 10.3 nm were obtained. All patents and publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition of a biologically active agent and a block copolymer composed of a poly(ethylene oxide) forming hydrophilic segment and a poly(butyl (alkyl)acrylate-co-(alkyl)acrylic acid) that is capable of forming supramolecular assemblies or micelles under favourable conditions. The supramolecular assemblies or micelles formed from said polymers associate or dissociate reversibly upon changes in the environmental pH. The pharmaceutical compositions of the present invention contain hydrophobic drugs, cations or polycationic compounds, which can be delivered to the body by oral route or other routes of administration.

Description

PHARMACEUTICAL COMPOSITIONS COMPRISING PH-SENSITIVE BLOCK COPOLYMERS AND A HYDRO PHOBIC DRUG
REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of pending U.S. S.N. 09/877,999, filed June 8, 2001 , the contents of which is incorporated herein by reference, in its entirety.
FIELD OF THE INVENTION
The present invention relates to stimuli responsive amphiphilic polymers forming supramolecular assemblies or micelles in the nanometric size range under favourable conditions. These supramolecular assemblies or micelles can be useful for the oral or parenteral delivery of hydrophobic or cationic pharmaceutical agents.
BACKGROUND OF THE INVENTION
Amphiphilic block copolymers having optimal hydrophilic and hydrophobic segments self-assemble spontaneously in aqueous environment forming micelles or supramolecular assemblies. These supramolecular assemblies exhibit core-shell architecture wherein the hydrophobic part forms the core and the hydrophilic part forms the corona. Recently, polymeric micelles have been widely used as drug delivery carriers for parenteral administration. Micellar dmg delivery carriers have several advantages including biocompatibility, solubilization of hydrophobic drugs in the core, nanometric size ranges which facilitate extravasation of the dmg carrier at the site of inflammation, site-specific delivery etc. (see for example Torchilin VP, J Controlled Release, 2001, 73, 137-172; Kataoka et al, Adv Dmg Deliv Rev, 2001, 47, 113-131; Jones et al, Eur J Phai Biopharm, 1999, 48, 101-111). A large number of amphiphilic block copolymers, having nonionic and/or charged hydrophobic and hydrophilic segments, that form micelles are reported in the literature. Examples of some widely used block copolymers for parenteral delivery include poly(ethylene oxide)-b-poly(D,L-lactide), poly(ethylene oxide)-b-poly(ε-caprolactone), poly(ethylene oxide)-b-poly(aspartic acid), poly(N-vinyl pyrrolidone)-b-poly(D,L-lactide) etc. US Patent 6,322,805 describes polymeric dmg carrier micelles prepared from amphiphilic block copolymer having a hydrophilic poly(alkylene oxide) component and a biodegradable hydrophobic component selected from a group consisting of poly(lactic acid), poly(lactic-co-glycolic acid), poly(ε-caprolactone) and a derivative thereof. These micelles are capable of solubilizing hydrophobic dmg in a hydrophilic environment. US Patent 6,338,859 describes polymeric micelle compositions where the hydrophilic component includes poly(N-vinyl-2-pyrrolidone) and the hydrophobic component is selected from a group consisting of polyesters, polyorthoesters, polyanhydride and derivatives thereof. The polyester group can be selected from poly(D,L- lactic acid), poly(glycolic acid), lactide/glycolide copolymers, poly(ε-caprolactone) and derivatives thereof. The micelle composition contains a therapeutic agent which can be an antitumor compound, hydrophobic antibiotic, hydrophobic antifungal agent, an immunomodulator, an antiviral dmg , or the like. US Patent 6,383,811 describes formation of complexes of polyions such as DNA with polyampholytes i.e. polymers possessing both cationic and anionic moieties, and delivery of the complex into the cell. US Patent 6,210,717 describes a composition composed of mixed polymeric micelles made of amphiphilic polyester-polycation copoly er and an amphiphilic polyester-sugar copolymer for delivery of nucleic acids into targeted host cells. The polyester-polycation forms an electrostatic interaction with polyanionic nucleic acids, and the polyester-sugar copolymer directs the micelle-nucleic acid complex to cells in vivo. US Patent 6,429,200 describes delivery of polynucleotides to cells using cleavable reverse micelles. Other molecules such as polymers, and surfactants containing disulphide linkages can be included into the complex micelles to enhance the delivery. US Patent 5,510,103 describes block copolymers having the hydrophilic and hydrophobic segments forming micelles and entrapping the hydrophobic drugs by physical methods. The hydrophilic segment is preferably poly(ethylene oxide) and hydrophobic segment is preferably poly(β-benzyl -L-aspartate) while the preferred dmg is adriamycin. US Patent 5,955,509 describes use of poly(vinyl-N-heterocycle)-b-poly(alkylene oxide) copolymers in micelle containing pharmaceutical formulations. These copolymers respond to pH changes in the environment and can be used to deliver therapeutic compounds at lower pH values. The micelles of these polymers remain intact at neutral pH, e.g. at physiological pH, while they will release the contents when exposed to a lower pH environment such as in the tumor. US Patent 6,497,895 describes hyperbranched micelles containing a core of mucic acid esters for the encapsulation of hydrophobic molecules. These polymers are useful for the transdermal delivery of the entrapped agent in a controlled manner. US Patent 6,387,406 describes compositions of the poly(oxyethylene)- poly(oxypropylene) block copolymers for oral delivery of biological agents. Nishiyama et al (Phar Res 2001, 18, 1035-1041 ; J Controlled Release 2001, 74, 83-94) have described the use of poly(ethylene oxide)-b-poly(α,β-aspartic acid) block copolymers forming micelles by interaction with an antitumor dmg, specifically cisplatin. Though the majority of these polymers can be used for oral delivery of bioactive agents, what is presently lacking are amphiphilic polymers capable of forming supramolecular assemblies that respond to an environmental stimuli such as pH change, thereby entrapping the contents in the micelle core at a low pH, such as that prevailing in the stomach, and rapidly releasing the contents at a higher pH, such as that prevailing in the intestine. In our earlier filed US patent application (S.N. 09/877,999, June 8, 2001) we describe a series of ionizable diblock copolymers useful for the delivery of bioactive agents. A series of the polymers in this patent application partially fulfills the above requirement. These polymers are different from those disclosed in US Patent 5,955,509 in that they form supramolecular assemblies at low pH, that could be dissociated upon increase in the pH above pKa of the carboxyl group. Another characteristic of these polymers is the presence of nonionizable and reversibly ionizable groups in the hydrophobic segment, where, hydrophobicity can be changed by controlling the ionization.
SUMMARY OF THE INVENTION
The present invention relates to polymers useful in combination with pharmaceutical compositions containing at least one biologically active agent. More particularly, the invention relates to block copolymers having hydrophilic and hydrophobic segments suitable for, but not limited to, oral drag delivery. More particularly, the hydrophilic segment of the polymers is nonionic and the hydrophobic segment contains at least one reversibly ionizable pendant carboxyl group conferring pH-sensitivity to the polymers. Accordingly, it is a primary objective of the instant invention to provide a copolymerf which is composed of a hydrophilic segment made of poly(ethylene oxide) and a hydrophobic segment composed of vinyl monomers containing at least one pendant carboxyl group. More particularly, the vinyl monomers included in the polymer are acrylic acid or methacrylic acid having pendant carboxyl groups and butyl (alkyl)acrylate where the butyl segment can be a linear or branched chain. Thus, the hydrophobic segment is a mixture of non-ionizable butyl (alkyl)acrylate and ionizable (alkyl)acrylic acid which controls the hydrophobicity of the polymer. Another objective of the instant invention is to prepare pharmaceutical compositions from the instantly disclosed polymers by entrapping at least one substance, preferably a biologically active agent, which is illustrated by, albeit not limited to a hydrophobic molecule, a cationic compound or macromolecule such as peptides and proteins bearing cationic residues. The entrapment can be physical (e.g. hydrophobic interaction, electrostatic interaction), or chemical (e.g. covalent linkage) in nature. A further objective of the present invention is to prepare supramolecular assemblies having core-shell structure wherein thβicore is formed by the hydrophobic segment, which can reversibly dissociate and associate in response to a change in environmental pH because of the pendant carboxyl group. The size of these supramolecular assemblies can be between 5 to 1000 nanometers thereby forming a solution or colloidal dispersion in water. It is to be noted that in the further text terms "micelles" and "supramolecular assemblies" are used interchangeably and essentially mean structures having a size range of between about 5 to 1000 nanometers. Yet another objective of the instant invention is to describe methods of entrapping the hydrophobic agents and cationic molecules in the supramolecular assemblies giving high incorporation efficiencies. A still further objective of the present invention is to use these supramolecular assemblies for delivery of a bioactive agent into the body by, but not limited to, the oral route. Upon oral administration, the hydrophobic molecule trapped in the core of the supramolecular assembly will be protected from the harsh acidic conditions of the stomach and released in the intestine due to dissociation of micelle at high pH. Other objectives and advantages of this invention will become apparent from the following description, inclusive of the experimental working examples, taken in conjunction with the accompanying drawings wherein are set forth, by way of illustration and example, certain embodiments of this invention. The drawings constitute a part of this specification and include exemplary embodiments of the instant invention and illustrate various objects and features thereof.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1. demonstrates in vitro release of progesterone from PEO-b-poly(nBAso-co- MAA50) supramolecular assemblies as a function of pH; Figure 2: demonstrates the effect of pH on intensity of light scattered by solution of PEO- b-poly(nBA5o-co-MAA5o); Figure 3. is a plot of plasma concentration versus time of fenofibrate upon oral administration of different formulations to Sprague-Dawley rats. DETAILED DESCRIPTION OF THE INVENTION
Abbrevations: nBA - n-butyl acrylate; MAA - methacrylic acid; EA - ethyl acrylate; PEO - poly(ethylene oxide). The present invention describes pharmaceutical compositions composed of block polymers composed of a poly(ethylene oxide) forming the hydrophilic segment and a poly(butyl (alkyl)acrylate-co-(alkyI)acrylic acid) forming the hydrophobic segment; and at least one biologically active agent. The molecular weight of the hydrophilic segment can be in the range of 200 to 80,000 Da, more preferably in the range of 500 to 10,000 Da, still more preferably in the range of 2,000 to 5,000 Da. The hydrophobic segments of the polymers in the present invention are composed of butyl (alkyl)acrylate and (alkyl)acrylic acid, where the alkyl chain is composed of from 0 to about 10 carbon atoms, inclusively, more preferably with 0 or 1 carbon atom. The butyl segment of the butyl (alkyl)acrylate can be a linear or branched chain including without limitation n-butyl and tert-butyl groups. The mole ratio of the butyl (alkyl)acrylate : (alkyl)acrylic acid in the hydrophobic segment is in the range of about 5:95 to 95:5, more preferably in the range of about 30:70 to 70:30. The length of the hydrophobic segment can be in the range of about 200 to 50,000, more preferably in the range of about 500 to 80,000 Da. Amphiphilic block copolymers have a tendency to self-assemble in water forming micelles. Upon micellization, the hydrophobic segment forms a core and the hydrophilic segment forms the corona of the micelles. The core of these micelles can be used as a reservoir of hydrophobic compounds protecting them form the external environment. If the hydrophobic segment of the polymer contains reversibly ionizable moieties, then the hydrophobicity of the segment could be manipulated by controlling the ionization of the moiety. Polymers of the present invention differ from other block copolymers in this aspect. In the polymers of the present invention, the hydrophobic segment is composed of the mixture of two monomers, one of them is butyl (alkyl) acrylate, which confers hydrophobicity to the segment. Butyl (alkyl)acrylate monomer is more preferably butyl acrylate or butyl methacrylate. The other monomer, (alkyl)acrylic acid has a pendant carboxyl group that can be reversibly ionized by changing the environmental pH. Thus, when the environmental pH is below the pKa of the carboxyl group, it will remain mostly in the unionized form and will confer hydrophobicity to the segment. This results in spontaneous aggregation of polymeric chains forming stable supramolecular assemblies or micelles in aqueous environment. However, when environmental pH is increased above pKa of the carboxyl group, its ionization will impart hydrophilicity to the hydrophobic segment. This may result in the dissociation of the micelle. (Alkyl)acrylic acid monomer is more preferably acrylic acid or methacrylic acid. These supramolecular assemblies are in the size range of from about 5 to 1000 nanometers. Hydrophobic drags are incorporated in the core of such supramolecular assemblies by methods that are known to one of ordinary skill in the art (see for example Lavasanifar et al J Controlled Release 2001, 77,155-60; Kohori et J Controlled Release 2002,78,155-63). Manipulation of the composition of the hydrophobic segment results in variation in the hydrophobicity of the polymer allowing control of the incorporation efficiencies of the hydrophobic drugs. Loadings in the range of 0.1 to 50% w/w more preferably in the range of 1 to 20% w/w of hydrophobic drugs are obtained using different drug loading procedures. Block copolymers of the present invention are used to prepare pharmaceutical compositions containing hydrophobic molecules. Non-limiting examples of the hydrophobic molecules includes hypolipidemic agents such as fenofibrate, anticancer agents such as doxorubicin, paclitaxel, docetaxel, camptothecin, megestrol acetate, teniposide, etoposide, antihypertensive agents such as candesartan cilexetil, non-steroidal, anti-inflammatory agents such as indomethacin, celecoxib, antiviral agents such as retinovir, amprenavir, indinavir, efavirenz, immunosuppressive agents such as cyclosporin A, sirolimus, tacrolimus, and similar agents belonging to other therapeutic classes. In an alternative embodiment of the present invention, the poly(butyl (alkyl)acrylate-co-(alkyl)acrylic acid) segment of the polymer will bear a negative charge at a pH above the pKa of carboxyl groups and form complexes with cationic molecules including without limitation polycations, peptides and proteins bearing cationic residues by electrostatic interactions. This will result in the partial or complete charge neutralization of polymer and/or cationic molecule thereby forming supramolecular assemblies or micelles. The cation or polycationic molecule will be entrapped in the core of such supramolecular assemblies. The term "cationic residues" refers to the functional groups imparting positive charge to the molecule such as cationic amino acids e.g. lysine, arginine, histidine or other functional groups such as primary, secondary, tertiary or quaternary amine groups present in the molecule. The complexes of poly(ethylene oxide)-block-poly(n-butyl acrylate-co-methacrylic acid) with poly-1-lysine are prepared in a buffer solution at pH 7.4. Supramolecular assemblies having unimodal size distribution within the size range of about 20 to 50 nm are obtained depending upon the molecular weight of the poly-1-lysine and composition of the polymer. On the other hand, complexes of poly(ethylene oxide)-block-poIy(ethyl acrylate-co-methacrylic acid) with poly-1-lysine in pH 7.4 buffer results in formation of aggregates having multimodal size distribution with sizes above about 200 nm. In yet another embodiment of the present invention, block copolymers are used to form stable coordination complexes with biologically active agents illustrated as metallic compounds such as cisplatin, carboplatin above the pKa of the carboxyl groups. The presence of butyl (alkyl)acrylate in the hydrophobic segment plays several crucial roles in forming stable supramolecular assemblies. It confers hydrophobicity to the polymer chain, which is one of the important driving forces in the self-assembly of polymeric chains. It also increases the incorporation of hydrophobic drugs in the supramolecular assemblies. It is well known that carboxylic acid groups form intra- and/or intermolecular hydrogen-bonding complexes with oxygen present in the polyethylene oxide chain (see for example Donini et al, Int J Pharm, 2002,245, 83-91; Lele et al, J. Controlled Release, 2000, 69, 237-248). This results in the formation of large aggregates or sometimes in precipitation of the complex. This problem could be possible in poly(ethylene oxide)-block-poly(aspartic acid) polymers (Nishiyama et al Pharm Res 2001, 18, 1035-1041; Yokoyama et al J Controlled release 1996, 39, 351-356). It was evident in polymers having the composition poly(ethylene oxide)-block-poly(methacrylic acid) as reported previously (Ranger et al J Polymer Science: part A: Polymer Chemistry, 2001, 39, 3861-3874). One method for overcoming this problem is by incorporating hydrophobic monomers such as ethyl acrylate in the hydrophobic segment, as disclosed in our earlier US patent application (09/877,999 June 8, 2001). In accordance with the instantly disclosed invention, it was observed that polymers with improved characteristics could be obtained by incorporating butyl (alkyl)acrylate in the hydrophobic segment. One of the major advantages of polymers in accordance with the present invention is the presence of the butyl chain of the butyl (alkyl)acrylate that largely minimizes formation of such hydrogen bonding complexes and can prevent formation of aggregates. This aids in the formation of stable supramolecular assemblies having uniform size range. For example, poly(ethylene oxide)-block-poly(n-butyl acrylate-co-methacrylic acid) with 50:50 mole ratio of n-butyl acrylate:methacrylic acid having molecular weight of about 5300 Da forms micelles of 30 nm at pH 5.0 while poly(ethylene oxide)-block- poly(ethyl acrylate-co-methacrylic acid) with 50:50 mole ratio of ethyl acrylate: methacrylic acid having molecular weight of about 5100 Da forms micelles of 120 nm at pH 5.0, which are possibly aggregates of several micelles. An oral route is the most preferred route of administration for a pharmaceutically active agent. For oral delivery, the compositions can be used in the form of tablets, capsules, powders, lozenges, solutions, suspensions, syrups, elixirs, and the like. The pharmaceutical compositions of the present invention are administered orally. The pharmaceutical compositions of the present invention can also be administered by a number of other routes, including without limitation, rectally, vaginally, topically, by pulmonary route, parenterally, including but not limited to intravenous, intra-arterial, intramuscular, intraperitoneal or subcutaneous route. The polymers in the present invention can be modified to attach targeting ligands such as lectin, antibodies or fragments of antibodies, peptides, vitamins or sugar molecules.
EXAMPLES
In all further text, figures appearing as subscript in the polymer composition indicate the mole ratio of that monomer present in the hydrophobic segment of the polymer.
Example 1
In vitro release of 3H-progesterone from PEO-b-poly(nBAs0-co-MAA5o) supramolecular assemblies at different pH:
Progesterone was used as a model hydrophobic drug to evaluate the effect of pH on drug release from supramolecular assemblies. 3H-progesterone was loaded in the supramolecular assemblies of PEO-b-poly(nBA5o-co-MAA5o) of molecular weight 5300 Da by film casting method. Briefly, 10 mg polymer, 1 mg progesterone and 1 μCi 3H- progesterone were dissolved in a mixture of dichloromethane, ethanol and water in a scintillation vial. The solvents were evaporated under reduced pressure to cast a film of polymer and drug on the glass surface. The film was hydrated with water to obtain the supramolecular assemblies, this solution was filtered through 2 μm filter to remove precipitated drag. For in vitro release study, the solution of progesterone loaded supramolecular assemblies was filled in a dialysis bag (6000-8000 Da molecular weight cut off) and the bag was put in a beaker containing 200 mL of simulated gastric fluid, pH 1.2 maintained at 37°C. The release medium was magnetically stirred. After 2 hours, the pH of medium was adjusted to 7.2 by addition of sodium hydroxide and potassium dihydrogen phosphate. During the entire release experiment, 1 mL samples of release medium were withdrawn periodically to measure the radioactivity of 3H-progesterone. As a control, the release of 3H-progesterone from supramolecular assemblies was also measured at pH 1.2, pH 7.2 and at pH 1.2 in absence of polymer. The results of the release experiment are shown in Figure 1. As shown in Figure 1, the progesterone is released rapidly in the absence of polymer at pH 1.2, suggesting that the dialysis bag does not form a barrier for the drag release. Further, the progesterone release from PEO-b-poly(nBA5o-co-MAAso) supramolecular assemblies is very rapid at pH 7.2, while slow at pH 1.2. On the other hand, when the pH of the release medium is changed from 1.2 to 7.2 after 2 hours, the release rate increases significantly. This is evidentiary of pH dependent dissociation of supramolecular assemblies. At pH 1.2, the polymer exists in the form of supramolecular assemblies due to unionized carboxyl groups and the drag is released slowly from the core of supramolecular assemblies. However, when the pH is increased to 7.2, the carboxyl groups become ionized resulting in the dissociation of supramolecular assemblies and the drug is released rapidly. To support this data, pH dependent aggregation behavior of PEO-b-poly(nBA5o-co- MAA5o) was studied using dynamic light scattering. Polymer solutions (0.5 mg/mL) were prepared in citrate phosphate universal buffer and the pH was adjusted between about 2.2- 7.0. The intensity of scattered light from these solutions at different pH was measured at 25°C and 90° angle and was plotted as a function of pH. The results are shown in Figure 2. From Figure 2, it is evident that the scattered light intensity is negligible at pH above ~5.5 while when the pH is decreased below 5.5, the intensity increases significantly suggesting association of polymeric chains. This indicates that below pH 5.5 the polymer is present in the form of supramolecular assemblies. The size of these supramolecular assemblies is in the range of 30- 100 nm depending upon the environmental pH. Example 2 Bioavailability studies of fenofibrate entrapped in supramolecular assemblies upon oral administration to rats Fenofibrate (FNB) was used as a model poorly water-soluble hydrophobic drug to evaluate the effect of drug incorporation in supramolecular assemblies on the bioavailability upon oral administration to rats. In a series of experiments, FNB incorporation was studied in different PEO-b-poly(EA-co-MAA) and PEO-b-poly(nBA5<r CO-MAA50) polymers by emulsion and film casting methods. The FNB loading was higher in PEO-b-poly(nBA5o-co-MAA5o) polymers. Therefore these polymers were used to evaluate relative bioavailability of FNB loaded supramolecular assemblies in Sprague- Dawleyrats. The study was conducted on 3 fenofibrate formulations, namely FNB supramolecular assemblies, FNB standard formulation and resuspended FNB. FNB loaded supramolecular assemblies were prepared from PEO-b-poIy(nBAso-co-MAA5o) of about molecular weight 5300 Da by film casting method. Size of the supramolecular assemblies was in the range of about 100-300 nm. FNB standard formulation was prepared by suspending the powder from Lipidil Macro® (Foumier) capsule in 0.5% w/v , carboxymethyl cellulose sodium (CMC Na) solution to obtain uniform suspension. FNB powder (Sigma) was also suspended in 0.5% w/v CMC Na solution to prepare resuspended FNB formulation which acts as a negative control. Rats were divided into 3 groups of 6 animals each. The rats were fasted overnight and fed with standard diet throughout the study. Each formulation was administered orally at a dose of 7.5 g/kg to 6 rats from a group. Blood was removed periodically from each rat, plasma was separated and stored at -80°C till further use. FNB content from the plasma was determined and plotted against time, the results of which are shown in Figure 3. The results show that FNB incorporated in supramolecular assemblies results in highest peak plasma level, ie. 10.9 μg/mL compared to 8.4 μg/mL for standard formulation. Also, tmax was achieved rapidly by FNB loaded supramolecular assemblies compared to standard formulation. Overall, the relative bioavailability of FNB was enhanced by 19% upon entrapment in supramolecular assemblies compared to standard FNB formulation, and the bioavailability enhancement was 133% compared to resuspended FNB powder. This enhancement in relative bioavailability is possibly due to release of drug from supramolecular assemblies in the nanoscopic size range, which increases the rate of dissolution of drag. Example 3 Formation of polyion complex micelles of PEO-ft-P(nBAso-co-MAAso) with poly-l- lysine Poly-1-lysine (PLL) of molecular weight 16,100 was used as a model cationic compound for formation of polyion micelles with PEO-b-P(EA50-co-MAA5o) and PEO-b-P(nBA5o-co- MAA50) copolymers with molecular weights of 5100 and 5700 Da, respectively. Polymer: PLL (-/+) charge ratios (mole: mole) of 1 : 1 and 2: 1 were used for complex formation. Stock solutions of polymer and PLL (molecular weight 16,100) having concentration of 2.5 mg/mL were prepared in phosphate buffer (pH 7.4) and mixed at room temperature to obtain 1 mg/mL final polymer concentration. The solution was filtered through 0.2 μm filter and size measurements were performed at 25°C using dynamic light scattering (DLS). The results are shown in Table 1. Table 1.Size of different polymer: PLL polyion micelles
Figure imgf000018_0001
The results of Table 1 show that complexation of PLL with PEO-b-P(EAso-co-MAA50) at different charge ratios results in formation of relatively large aggregates which could be attributed to the hydrogen bonding between poly(ethylene oxide) chain and carboxyl groups. In contrast, the complexation of PLL with PEO-b-P(nBA5o-co-MAA5o) at similar ratios results in formation of micelles having unimodal size distribution and low polydispersity indices. Similar complexes are obtained with PLL of different molecular weights.
Example 4 Complexation of PEO-b-P(nBAso-co-MAASo) with verapamil hydrochloride Verapamil hydrochloride was used as a model cationic drug. Solutions of PEO-b-P(nBA50- co-MAA50) and verapamil hydrochloride in universal buffer were mixed to obtain final polymer concentration of 0.5 mg/mL and verapamil hydrochloride concentration of 0.8 mg/mL. The solution pH was adjusted to 6.1 and size was measured using DLS. Polyion complex micelles of 38 ± 10.3 nm were obtained. All patents and publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. It is to be understood that while a certain form of the invention is illustrated, it is not to be limited to the specific form or arrangement of parts herein described and shown. It will be apparent to those skilled in the art that various changes may be made without departing from the scope of the invention and the invention is not to be considered limited to what is shown and described in the specification and drawings. One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The compounds, compositions, biologically related compounds, methods, procedures and techniques described herein are presently representative of the preferred embodiments, are intended to be exemplary and are not intended as limitations on the scope. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention and are defined by the scope of the appended claims. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims.

Claims

What is claimed is: L A pharmaceutical composition comprising: a diblock copolymer of poly(ethylene oxide) and poly(butyl (alkyl)acrylate-co- (alkyl)acrylic acid); and at least one biologically active agent.
2. The polymer of claim 1 wherein said poly(ethylene oxide) segment has a molecular weight in the range of about 200-80,000 Da.
3. The polymer of claim 1 wherein said poly(butyl (alkyl)acrylate-co-(alkyl)acrylic acid) segment has a molecular weight in the range of about 200-80,000 Da.
4. The polymer of claim 1 wherein said alkyl is an alkyl chain having from 0 to about 10 carbon atoms.
5. The polymer of claim 1 wherein said butyl portion of the butyl (alkyl)acrylate is a linear or branched chain.
6. The polymer of claim 1 wherein said butyl (alkyl)acrylate : (alkyl)acrylic acid is in a molar ratio in the range of about 5:95 to 95:5.
7. The pharmaceutical composition of claim 1 wherein said diblock polymer is poly(ethylene oxide)-block-poly(n-butyl acrylate-co-methacrylic acid) having an n- butyl acrylate: methacrylic acid molar ratio of about 50:50.
8. The pharmaceutical composition of claim 1 in the form of supramolecular assemblies or micelles.
9. The pharmaceutical composition of claim 8 wherein said supramolecular assemblies or micelles are in a size range of about 5 to 1000 nanometers.
10. The pharmaceutical composition of claim 8 wherein said supramolecular assemblies associate or dissociate reversibly in response to environmental pH changes.
11. The pharmaceutical composition of claim 1 wherein release rate of said biologically active agent increases with increase in pH.
12. The pharmaceutical composition of claim 8 wherein the biologically active agent is a hydrophobic drug incorporated in said supramolecular assemblies by physical or chemical methods.
13. The pharmaceutical composition of claim 12 wherein the hydrophobic drag is fenofibrate.
14. The pharmaceutical composition of claim 8 wherein the biologically active agent is a cation or polycation.
15. The pharmaceutical composition of claim 14 wherein said polycation is a peptide or protein bearing cationic residues.
16. The pharmaceutical composition of claim 14 wherein the cation or polycation interacts electrostatically with said (alkyl)acrylic acid units.
17. The pharmaceutical composition of claim 14 wherein the cation is verapamil hydrochloride.
18. The pharmaceutical composition of claim 8 wherein the biologically active agent forms metal coordination complexes with said (alkyl)acrylic acid units.
19. The pharmaceutical composition of claim 18 wherein the biologically active agent is cisplatin.
20. The pharmaceutical composition of claim 18 wherein the biologically active agent is carboplatin.
21. The pharmaceutical composition of claim 12 wherein incorporation of a hydrophobic drag in the supramolecular assemblies enhances the bioavailability of the hydrophobic drug upon oral administration.
22. The pharmaceutical composition of claim 8 which is administered by oral, intravenous, intra-arterial, subcutaneous, intramuscular, intraperitoneal, rectal, vaginal or topical route.
23. The pharmaceutical composition of claim 8 having a targeting ligand on a surface thereof.
PCT/CA2004/000561 2003-06-25 2004-04-14 Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug WO2004112757A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP04727195A EP1638539B1 (en) 2003-06-25 2004-04-14 Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug
SI200431088T SI1638539T1 (en) 2003-06-25 2004-04-14 Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug
CA2530736A CA2530736C (en) 2003-06-25 2004-04-14 Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug
DK04727195T DK1638539T3 (en) 2003-06-25 2004-04-14 Pharmaceutical compositions comprising pH-sensitive block copolymers and a hydrophobic drug
PL04727195T PL1638539T3 (en) 2003-06-25 2004-04-14 Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug
MXPA05014017A MXPA05014017A (en) 2003-06-25 2004-04-14 Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug.
JP2006515571A JP4619357B2 (en) 2003-06-25 2004-04-14 Pharmaceutical composition comprising a pH sensitive block copolymer and a hydrophobic drug
AU2004248863A AU2004248863B2 (en) 2003-06-25 2004-04-14 Pharmaceutical compositions comprising pH-sensitive block copolymers and a hydrophobic drug
BRPI0411872-3A BRPI0411872A (en) 2003-06-25 2004-04-14 pharmaceutical composition
DE602004018772T DE602004018772D1 (en) 2003-06-25 2004-04-14 PHARMACEUTICAL COMPOSITIONS - CONTAINING PH SENSITIVE BLOCK COPOLYMERS AND A HYDROPHOBIC ACTIVE SUBSTANCE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/607,446 US7094810B2 (en) 2001-06-08 2003-06-25 pH-sensitive block copolymers for pharmaceutical compositions
US10/607,446 2003-06-25

Publications (1)

Publication Number Publication Date
WO2004112757A1 true WO2004112757A1 (en) 2004-12-29

Family

ID=33540273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/000561 WO2004112757A1 (en) 2003-06-25 2004-04-14 Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug

Country Status (16)

Country Link
US (1) US7094810B2 (en)
EP (1) EP1638539B1 (en)
JP (1) JP4619357B2 (en)
AT (1) ATE418970T1 (en)
AU (1) AU2004248863B2 (en)
BR (1) BRPI0411872A (en)
CA (1) CA2530736C (en)
CY (1) CY1110264T1 (en)
DE (1) DE602004018772D1 (en)
DK (1) DK1638539T3 (en)
ES (1) ES2323701T3 (en)
MX (1) MXPA05014017A (en)
PL (1) PL1638539T3 (en)
PT (1) PT1638539E (en)
SI (1) SI1638539T1 (en)
WO (1) WO2004112757A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005079856A1 (en) * 2004-02-23 2005-09-01 The University Of British Columbia Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules
WO2008035229A2 (en) * 2006-09-22 2008-03-27 Labopharm, Inc. Compositions and methods for ph targeted drug delivery
WO2009050555A2 (en) * 2007-10-19 2009-04-23 Coatex S.A.S. Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof
EP2305275A1 (en) * 2008-06-24 2011-04-06 NanoCarrier Co., Ltd. Liquid composition comprising cisplatin-coordinating compound

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523544A (en) * 2000-02-17 2003-08-05 レックスマーク・インターナショナル・インコーポレーテツド Composition containing fine particles for supporting biologically active substance thereon or having the same supported thereon and method for preparing these
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
KR20090045205A (en) * 2006-06-26 2009-05-07 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. Active agent formulations, methods of making, and methods of use
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US8685417B2 (en) * 2006-12-20 2014-04-01 Arkema, Inc. Polymer encapsulation and/or binding
US20100136124A1 (en) * 2007-04-20 2010-06-03 University Of South Australia Nanoparticle-coated capsule formulation for dermal drug delivery
US8003621B2 (en) * 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
TWI388591B (en) * 2008-03-28 2013-03-11 Ind Tech Res Inst Thermosensitive material
US8778400B2 (en) * 2008-04-21 2014-07-15 University Of South Australia Nanoparticle-stabilized capsule formulation for treatment of inflammation
CN102065902A (en) * 2008-05-13 2011-05-18 华盛顿大学 Polymeric carrier
US20110142951A1 (en) * 2008-05-13 2011-06-16 University Of Washington Micelles for intracellular delivery of therapeutic agents
EP2281011B1 (en) * 2008-05-13 2013-02-27 University Of Washington Diblock copolymers and polynucleotide complexes thereof for delivery into cells
CN102066444A (en) 2008-05-13 2011-05-18 华盛顿大学 Micellic assemblies
WO2009140423A2 (en) * 2008-05-13 2009-11-19 University Of Washington Targeted polymer bioconjugates
KR101638201B1 (en) * 2008-05-16 2016-07-08 유니버시티 오브 시드니 Administrable compositions
CA2635187A1 (en) * 2008-06-05 2009-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University Oligonucleotide duplexes and uses thereof
EP2331069A4 (en) 2008-08-22 2011-10-26 Univ Washington Heterogeneous polymeric micelles for intracellular delivery
WO2010053596A1 (en) 2008-11-06 2010-05-14 University Of Washington Bispecific intracellular delivery vehicles
CA2742880A1 (en) 2008-11-06 2010-05-14 University Of Washington Multiblock copolymers
JP2012511053A (en) 2008-12-08 2012-05-17 ユニヴァーシティ オブ ワシントン Omega functionalized polymers, junction functionalized block copolymers, and radical chain extension polymerization
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
TWI374903B (en) * 2008-12-31 2012-10-21 Ind Tech Res Inst Biodegradable copolymer hydrogel materials
WO2011062965A2 (en) 2009-11-18 2011-05-26 University Of Washington Through Its Center For Commercialization Targeting monomers and polymers having targeting blocks
AU2014296278C1 (en) 2013-07-30 2023-02-02 Genevant Sciences Gmbh Block copolymers and their conjugates or complexes with oligonucleotides
AU2016209295B2 (en) 2015-01-21 2021-08-12 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
WO2017156183A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
US10064855B2 (en) 2016-03-08 2018-09-04 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
CN106432647B (en) * 2016-09-26 2018-10-30 华南理工大学 PH response block polymers and its mixed micelle based on tertiary amino and application
WO2018126084A1 (en) 2016-12-30 2018-07-05 Phaserx, Inc. Branched peg molecules and related compositions and methods
WO2019032975A1 (en) * 2017-08-10 2019-02-14 Mec Device Pharma International Llc Abuse-resistant drug formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955509A (en) * 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
WO2001087227A2 (en) * 2000-05-17 2001-11-22 Labopharm, Inc. Drug containing polymeric micelles
US6491903B1 (en) * 1996-06-27 2002-12-10 Washington University Particles comprising amphiphilic copolymers
WO2004035013A2 (en) * 2002-10-21 2004-04-29 L'oreal Process for dissolving lipophilic compounds, and cosmetic composition

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1411843A (en) * 1973-02-28 1975-10-29 Univ Strathclyde Method of modifying the properties of a polymer
JPS5767860A (en) * 1980-10-15 1982-04-24 Fuji Photo Film Co Ltd Material for multilayer analysis
JP2517760B2 (en) * 1989-05-11 1996-07-24 新技術事業団 Water-soluble polymerized pharmaceutical preparation
KR940003548U (en) * 1992-08-14 1994-02-21 김형술 Laundry dryer
US5840319A (en) * 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
EP0639592A1 (en) * 1993-08-18 1995-02-22 Nippon Shokubai Co., Ltd. Water-soluble graft polymers and production process thereof
WO1995025764A1 (en) * 1994-03-23 1995-09-28 Meiji Seika Kabushiki Kaisha Double-stranded derivative of polyoxyethylene-containing lipid
US5620850A (en) * 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US6221959B1 (en) * 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
AU4690596A (en) 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
US5492996A (en) * 1995-02-21 1996-02-20 The United States Of America As Represented By The Secretary Of The Air Force Alcohol soluble benzazole polymers
BR9608330A (en) * 1995-04-19 1999-11-30 Kazunori Kataoka Heterotelequelic block copolymer and a method for its production.
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
HUP9900662A3 (en) * 1995-08-10 2006-04-28 Kataoka Kazunori Block polymer having functional groups at both ends
US5770627A (en) * 1995-08-16 1998-06-23 University Of Washington Hydrophobically-modified bioadhesive polyelectrolytes and methods relating thereto
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
EP0894043B1 (en) 1996-03-15 2001-10-31 President And Fellows Of Harvard College Method of forming articles and patterning surfaces via capillary micromolding
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US6235309B1 (en) 1997-02-28 2001-05-22 The Regents Of The University Of California Inhibition of cell-cell binding by lipid assemblies
EP0963758A3 (en) 1998-05-07 2000-03-22 Universiteit Gent Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells
US5939453A (en) * 1998-06-04 1999-08-17 Advanced Polymer Systems, Inc. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
WO2000002950A1 (en) * 1998-07-13 2000-01-20 Expression Genetics, Inc. Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier
DE19919785A1 (en) * 1999-04-30 2000-12-07 Wella Ag Hair treatment agent with polymers of unsaturated saccharides, unsaturated saccharic acids or their derivatives
DE10008895A1 (en) * 2000-02-25 2001-08-30 Beiersdorf Ag Stabilization of active substances that are sensitive to oxidation and / or UV
US6780428B2 (en) * 2001-06-08 2004-08-24 Labopharm, Inc. Unimolecular polymeric micelles with an ionizable inner core
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
GB0131112D0 (en) * 2001-12-31 2002-02-13 Univ London Pharmacy Block copolymers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955509A (en) * 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
US6491903B1 (en) * 1996-06-27 2002-12-10 Washington University Particles comprising amphiphilic copolymers
WO2001087227A2 (en) * 2000-05-17 2001-11-22 Labopharm, Inc. Drug containing polymeric micelles
WO2004035013A2 (en) * 2002-10-21 2004-04-29 L'oreal Process for dissolving lipophilic compounds, and cosmetic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FREIJ-LARSSON C ET AL: "Polyurethane surfaces modified by amphiphilic polymers: effects on protein adsorption", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 3, February 2000 (2000-02-01), pages 307 - 315, XP004243982, ISSN: 0142-9612 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005079856A1 (en) * 2004-02-23 2005-09-01 The University Of British Columbia Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules
WO2008035229A2 (en) * 2006-09-22 2008-03-27 Labopharm, Inc. Compositions and methods for ph targeted drug delivery
WO2008035229A3 (en) * 2006-09-22 2009-08-13 Labopharm Inc Compositions and methods for ph targeted drug delivery
JP2010504318A (en) * 2006-09-22 2010-02-12 ラボファーム インコーポレイテッド Compositions and methods for pH targeted drug delivery
WO2009050555A2 (en) * 2007-10-19 2009-04-23 Coatex S.A.S. Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof
FR2922452A1 (en) * 2007-10-19 2009-04-24 Coatex S A S Soc Par Actions S FORMULATIONS OF ORGANOPLATINIC COMPOUNDS IN THE PRESENCE OF ASSOCIATIVE POLYMERS, PRODUCTS OBTAINED AND USES THEREOF
WO2009050555A3 (en) * 2007-10-19 2009-06-04 Coatex Sas Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof
EP2305275A1 (en) * 2008-06-24 2011-04-06 NanoCarrier Co., Ltd. Liquid composition comprising cisplatin-coordinating compound
EP2305275A4 (en) * 2008-06-24 2012-07-18 Nanocarrier Co Ltd Liquid composition comprising cisplatin-coordinating compound
US8895076B2 (en) 2008-06-24 2014-11-25 Nanocarrier Co., Ltd. Liquid composition of cisplatin coordination compound

Also Published As

Publication number Publication date
DE602004018772D1 (en) 2009-02-12
BRPI0411872A (en) 2006-08-08
EP1638539B1 (en) 2008-12-31
AU2004248863B2 (en) 2009-03-12
PL1638539T3 (en) 2009-10-30
MXPA05014017A (en) 2007-01-31
CA2530736A1 (en) 2004-12-29
DK1638539T3 (en) 2009-05-04
CA2530736C (en) 2013-07-02
EP1638539A1 (en) 2006-03-29
JP2007505029A (en) 2007-03-08
US7094810B2 (en) 2006-08-22
US20040072784A1 (en) 2004-04-15
JP4619357B2 (en) 2011-01-26
ATE418970T1 (en) 2009-01-15
CY1110264T1 (en) 2015-01-14
AU2004248863A1 (en) 2004-12-29
PT1638539E (en) 2009-04-09
ES2323701T3 (en) 2009-07-23
SI1638539T1 (en) 2009-10-31

Similar Documents

Publication Publication Date Title
EP1638539B1 (en) Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug
JP4302509B2 (en) Water-soluble stable self-assembled polyelectrolytes
Gaucher et al. Block copolymer micelles: preparation, characterization and application in drug delivery
AU2007333528B2 (en) Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
AU2002315598A1 (en) Water-soluble stabilized self-assembled polyelectrolytes
WO2002000194A2 (en) Polymeric micelle compositions
Gautier et al. Preparation of poly (D, L-lactide) nanoparticles assisted by amphiphilic poly (methyl methacrylate-co-methacrylic acid) copolymers
Hu et al. RTG-loaded nanomicelles (CS–VES–NAC) for oral anti-HIV drug delivery
EP3148590A1 (en) Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
Chatenay-Malabry CHRISTINE VAUTHIER, PATRICK COUVREUR, and CATHERINE DUBERNET Université de Paris Sud

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004248863

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/014017

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004727195

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2530736

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006515571

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004248863

Country of ref document: AU

Date of ref document: 20040414

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004248863

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004727195

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0411872

Country of ref document: BR